Zhenzhen Yin

Research Fellow

Zhenzhen Yin

Research Fellow

Publications

Hide
Lu S, Yin Z, Wu L, Sun Y, Chen J, Wu LMN, Oblinger JL, Blake DC, Landegger LD, Seist R, Ho W, Xiu B, Jones AP, Muzikansky A, Stankovic KM, Plotkin SR, Chang LS, Xu L
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model.
bioRxiv. 2024;:ePub - PMID: 39763968 - PMCID: PMC11703165 - DOI: 10.1101/2024.12.29.630658
Sun Y, Yin Z, Li S, Wu L, Zhang Y, Zhao Y, Gomes Dos Santos IL, Subudhi S, Lei P, Muzikansky A, Yuan Z, Rueda BR, Jain RK, Xu L
Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.
Br J Cancer. 2024;131(10):1683-1693 - PMID: 39369055 - PMCID: PMC11554678 - DOI: 10.1038/s41416-024-02863-9
Lu S, Yin Z, Chen J, Wu L, Sun Y, Gao X, Huang P, Jordan JT, Plotkin SR, Xu L
Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis.
Cancers (Basel). 2024;16(11):ePub - PMID: 38893082 - PMCID: PMC11171041 - DOI: 10.3390/cancers16111961
Wu L, Vasilijic S, Sun Y, Chen J, Landegger LD, Zhang Y, Zhou W, Ren J, Early S, Yin Z, Ho WW, Zhang N, Gao X, Lee GY, Datta M, Sagers JE, Brown A, Muzikansky A, Stemmer-Rachamimov A, Zhang L, Plotkin SR, Jain RK, Stankovic KM, Xu L
Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.
Sci Transl Med. 2021;13(602):ePub - PMID: 34261799 - PMCID: PMC8409338 - DOI: 10.1126/scitranslmed.abd4816